{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:13:52Z","timestamp":1792192432254,"version":"4.4.0"},"reference-count":98,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Polycythemia vera (PV) is a hematopoietic stem cell neoplasm defined by activating somatic mutations in the JAK2 gene and characterized clinically by overproduction of red blood cells, platelets, and neutrophils; a significant burden of disease-specific symptoms; high rates of vascular events; and evolution to a myelofibrosis phase or acute leukemia. The JAK2V617F variant allele frequency (VAF) is a key determinant of outcomes in PV, including thrombosis and myelofibrotic progression. Here, we critically review the dynamic role of JAK2V617F mutation burden in the pathogenesis and natural history of PV, the suitability of JAK2V617F VAF as a diagnostic and prognostic biomarker, and the utility of JAK2V617F VAF reduction in PV treatment.<\/jats:p>","DOI":"10.1182\/blood.2022017697","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T16:17:32Z","timestamp":1675700252000},"page":"1934-1942","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":110,"title":["<i>JAK2<\/i>\n                    V617F allele burden in polycythemia vera: burden of proof"],"prefix":"10.1182","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8673-4317","authenticated-orcid":false,"given":"Alison R.","family":"Moliterno","sequence":"first","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6645-154X","authenticated-orcid":false,"given":"Hannah","family":"Kaizer","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2106-3698","authenticated-orcid":false,"given":"Brandi N.","family":"Reeves","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, Blood Research Center, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2023110216015419700_bib1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2023110216015419700_bib2","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.6004\/jnccn.2022.0046","article-title":"Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Gerds","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"17","key":"2023110216015419700_bib3","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJMc1502524","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2023110216015419700_bib4","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood-2008-02-137877","article-title":"The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity","volume":"112","author":"James","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2023110216015419700_bib5","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.exphem.2008.05.006","article-title":"Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens","volume":"36","author":"Moliterno","year":"2008","journal-title":"Exp Hematol"},{"issue":"13","key":"2023110216015419700_bib6","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1182\/blood-2012-05-431791","article-title":"JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone","volume":"120","author":"Godfrey","year":"2012","journal-title":"Blood"},{"issue":"18","key":"2023110216015419700_bib7","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/bloodadvances.2022007128","article-title":"Hematopoietic fitness of JAK2V617F myeloproliferative neoplasms is linked to clinical outcome","volume":"6","author":"Abu-Zeinah","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"2023110216015419700_bib8","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"issue":"9","key":"2023110216015419700_bib9","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41375-021-01183-8","article-title":"Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival","volume":"35","author":"Abu-Zeinah","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"2023110216015419700_bib10","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1182\/bloodadvances.2019001407","article-title":"Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden","volume":"4","author":"Karantanos","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"2023110216015419700_bib11","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A\u00a0prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"issue":"6","key":"2023110216015419700_bib12","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1600-0609.2007.00960.x","article-title":"The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype","volume":"79","author":"Larsen","year":"2007","journal-title":"Eur J Haematol"},{"key":"2023110216015419700_bib13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/bs.ircmb.2021.02.009","article-title":"Lessons from mouse models of MPN","volume":"366","author":"Benlabiod","year":"2022","journal-title":"Int Rev Cell Mol Biol"},{"issue":"1","key":"2023110216015419700_bib14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1182\/blood-2012-01-402396","article-title":"Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera","volume":"120","author":"Mullally","year":"2012","journal-title":"Blood"},{"issue":"26","key":"2023110216015419700_bib15","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1182\/blood.2019001163","article-title":"Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells","volume":"134","author":"Mansier","year":"2019","journal-title":"Blood"},{"issue":"8","key":"2023110216015419700_bib16","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1182\/blood-2015-06-652941","article-title":"Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms","volume":"128","author":"Hinds","year":"2016","journal-title":"Blood"},{"issue":"7831","key":"2023110216015419700_bib17","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41586-020-2786-7","article-title":"Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells","volume":"586","author":"Bao","year":"2020","journal-title":"Nature"},{"issue":"7939","key":"2023110216015419700_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41586-022-05448-9","article-title":"Common and rare variant associations with clonal haematopoiesis phenotypes","volume":"612","author":"Kessler","year":"2022","journal-title":"Nature"},{"key":"2023110216015419700_bib19","doi-asserted-by":"crossref","first-page":"100280","DOI":"10.1016\/j.eclinm.2020.100280","article-title":"Loss-of-function polymorphism in IL6R reduces risk of JAK2V617F somatic mutation and myeloproliferative neoplasm: a Mendelian randomization study","volume":"21","author":"Pedersen","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2023110216015419700_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.ircmb.2021.08.001","article-title":"The roles of sex and genetics in the MPN","volume":"366","author":"Moliterno","year":"2022","journal-title":"Int Rev Cell Mol Biol"},{"issue":"17","key":"2023110216015419700_bib21","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1182\/bloodadvances.2022007201","article-title":"Real world study of children and young adults with myeloproliferative neoplasms identifying risks and unmet needs","volume":"6","author":"Sobas","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"2023110216015419700_bib22","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3324\/haematol.2009.014407","article-title":"Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders","volume":"95","author":"Stein","year":"2010","journal-title":"Haematologica"},{"issue":"5","key":"2023110216015419700_bib23","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.2019001113","article-title":"Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population","volume":"134","author":"Cordua","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2023110216015419700_bib24","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1038\/s41375-021-01159-8","article-title":"Early detection of myeloproliferative neoplasms in a Danish general population study","volume":"35","author":"Cordua","year":"2021","journal-title":"Leukemia"},{"issue":"7512","key":"2023110216015419700_bib25","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature13383","article-title":"Neuropathy of haematopoietic stem\u00a0cell niche is essential for myeloproliferative neoplasms","volume":"512","author":"Arranz","year":"2014","journal-title":"Nature"},{"issue":"1","key":"2023110216015419700_bib26","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1038\/s41467-022-32927-4","article-title":"Inhibition of interleukin-1\u03b2 reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm","volume":"13","author":"Rai","year":"2022","journal-title":"Nat Commun"},{"issue":"19","key":"2023110216015419700_bib27","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1182\/blood-2014-04-570572","article-title":"JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2","volume":"124","author":"Kagoya","year":"2014","journal-title":"Blood"},{"issue":"28","key":"2023110216015419700_bib28","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1038\/s41388-019-0813-7","article-title":"Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation","volume":"38","author":"Stetka","year":"2019","journal-title":"Oncogene"},{"issue":"4","key":"2023110216015419700_bib29","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/s41375-019-0629-z","article-title":"Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms","volume":"34","author":"Baumeister","year":"2020","journal-title":"Leukemia"},{"issue":"26","key":"2023110216015419700_bib30","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1182\/blood-2017-05-784942","article-title":"Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms","volume":"130","author":"Nieborowska-Skorska","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2023110216015419700_bib31","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/leu.2013.102","article-title":"A\u00a0role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression","volume":"27","author":"Marty","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"2023110216015419700_bib32","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1158\/2159-8290.CD-20-1353","article-title":"LKB1\/STK11 Is a tumor suppressor in the progression of myeloproliferative neoplasms","volume":"11","author":"Marinaccio","year":"2021","journal-title":"Cancer Discov"},{"issue":"3","key":"2023110216015419700_bib33","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1600-0609.1997.tb00971.x","article-title":"Increase of CD34 positive cells in polycythaemia vera","volume":"59","author":"Andr\u00e9asson","year":"1997","journal-title":"Eur J Haematol"},{"issue":"12","key":"2023110216015419700_bib34","doi-asserted-by":"crossref","first-page":"e0251995","DOI":"10.1371\/journal.pone.0251995","article-title":"Tmprss6-ASO as a tool for the treatment of polycythemia vera mice","volume":"16","author":"Casu","year":"2021","journal-title":"PLoS One"},{"key":"2023110216015419700_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2022.01.011","article-title":"JAK2 allele burden is correlated with a risk of venous but not arterial thrombosis","volume":"211","author":"Soudet","year":"2022","journal-title":"Thromb Res"},{"issue":"2","key":"2023110216015419700_bib36","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3324\/haematol.2010.031070","article-title":"Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3","volume":"96","author":"Barbui","year":"2011","journal-title":"Haematologica"},{"issue":"3","key":"2023110216015419700_bib37","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/bjh.17848","article-title":"Revisiting Diagnostic performances of serum erythropo\u00efetin level and JAK2 mutation for polycythemias: analysis of a cohort of 1090 patients with red cell mass measurement","volume":"196","author":"Maslah","year":"2022","journal-title":"Br J Haematol"},{"issue":"12","key":"2023110216015419700_bib38","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41408-021-00581-6","article-title":"JAK2V617F variant allele frequency &gt;50% identifies patients with polycythemia vera at high risk for venous thrombosis","volume":"11","author":"Guglielmelli","year":"2021","journal-title":"Blood Cancer J"},{"issue":"7913","key":"2023110216015419700_bib39","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41586-022-04785-z","article-title":"The longitudinal dynamics and natural history of clonal haematopoiesis","volume":"606","author":"Fabre","year":"2022","journal-title":"Nature"},{"issue":"6485","key":"2023110216015419700_bib40","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1126\/science.aay9333","article-title":"The evolutionary dynamics and fitness landscape of clonal hematopoiesis","volume":"367","author":"Watson","year":"2020","journal-title":"Science"},{"issue":"9","key":"2023110216015419700_bib41","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3324\/haematol.2014.107631","article-title":"JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate","volume":"99","author":"Nielsen","year":"2014","journal-title":"Haematologica"},{"issue":"9","key":"2023110216015419700_bib42","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41408-021-00552-x","article-title":"Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera","volume":"11","author":"Liu","year":"2021","journal-title":"Blood Cancer J"},{"issue":"10","key":"2023110216015419700_bib43","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41375-018-0207-9","article-title":"Dysregulated iron metabolism in polycythemia vera: etiology and consequences","volume":"32","author":"Ginzburg","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"2023110216015419700_bib44","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1182\/bloodadvances.2019001379","article-title":"Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia","volume":"4","author":"Gangaraju","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2023110216015419700_bib45","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2015-10-676742","article-title":"Minihepcidin peptides as disease modifiers in mice affected by \u03b2-thalassemia and polycythemia vera","volume":"128","author":"Casu","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2023110216015419700_bib46","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/jth.12884","article-title":"Increased expression of HIF2\u03b1 during iron deficiency-associated megakaryocytic differentiation","volume":"13","author":"Jimenez","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"issue":"436","key":"2023110216015419700_bib47","doi-asserted-by":"crossref","first-page":"eaan8292","DOI":"10.1126\/scitranslmed.aan8292","article-title":"Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms","volume":"10","author":"Wolach","year":"2018","journal-title":"Sci Transl Med"},{"issue":"2","key":"2023110216015419700_bib48","doi-asserted-by":"crossref","first-page":"E37","DOI":"10.1002\/ajh.26402","article-title":"Tissue factor activity is increased in neutrophils from JAK2 V617F-mutated essential thrombocythemia and polycythemia vera patients","volume":"97","author":"Reeves","year":"2022","journal-title":"Am J Hematol"},{"issue":"10","key":"2023110216015419700_bib49","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1172\/JCI90312","article-title":"JAK2-V617F promotes venous thrombosis through \u03b21\/\u03b22 integrin activation","volume":"128","author":"Edelmann","year":"2018","journal-title":"J\u00a0Clin Invest"},{"issue":"5","key":"2023110216015419700_bib50","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ejim.2015.03.009","article-title":"High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms","volume":"26","author":"Enblom","year":"2015","journal-title":"Eur J Intern Med"},{"issue":"9","key":"2023110216015419700_bib51","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/blood.2020008043","article-title":"Clinical insights into the origins of thrombosis in myeloproliferative neoplasms","volume":"137","author":"Moliterno","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2023110216015419700_bib52","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1002\/cam4.2886","article-title":"Thrombosis among 1537 patients with JAK2(V617F) -mutated myeloproliferative neoplasms: risk\u00a0factors and development of a predictive model","volume":"9","author":"Zhang","year":"2020","journal-title":"Cancer Med"},{"issue":"8","key":"2023110216015419700_bib53","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.numecd.2022.04.013","article-title":"Neutrophil-lymphocyte ratio and carotid plaque burden in patients with essential thrombocythemia and polycythemia vera","volume":"32","author":"Kwon","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"2023110216015419700_bib54","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/blood-2006-03-009472","article-title":"JAK2(V617F): prevalence in a large Chinese hospital population","volume":"109","author":"Xu","year":"2007","journal-title":"Blood"},{"issue":"26","key":"2023110216015419700_bib55","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023110216015419700_bib56","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3324\/haematol.2010.033191","article-title":"The JAK2 V617F somatic mutation, mortality and cancer risk in the general population","volume":"96","author":"Nielsen","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"2023110216015419700_bib57","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/bjh.12099","article-title":"Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population","volume":"160","author":"Nielsen","year":"2013","journal-title":"Br J Haematol"},{"issue":"3","key":"2023110216015419700_bib58","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.stem.2021.02.001","article-title":"Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms","volume":"28","author":"Van Egeren","year":"2021","journal-title":"Cell Stem Cell"},{"issue":"7895","key":"2023110216015419700_bib59","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41586-021-04312-6","article-title":"Life histories of myeloproliferative neoplasms inferred from phylogenies","volume":"602","author":"Williams","year":"2022","journal-title":"Nature"},{"issue":"5","key":"2023110216015419700_bib60","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","article-title":"Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b","volume":"36","author":"Kiladjian","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"2023110216015419700_bib61","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","article-title":"Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial","volume":"8","author":"Barbui","year":"2021","journal-title":"Lancet Haematol"},{"issue":"3","key":"2023110216015419700_bib62","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"2023110216015419700_bib63","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol"},{"issue":"11","key":"2023110216015419700_bib64","first-page":"790","article-title":"Physiopathology and course of polycythemia vera as related to therapy","volume":"142","author":"Dameshek","year":"1950","journal-title":"J\u00a0Am Med Assoc"},{"issue":"4","key":"2023110216015419700_bib65","doi-asserted-by":"crossref","first-page":"101330","DOI":"10.1016\/j.beha.2021.101330","article-title":"Advances in polycythemia vera and lessons for acute leukemia","volume":"34","author":"Spivak","year":"2021","journal-title":"Best Pract Res Clin Haematol"},{"issue":"22","key":"2023110216015419700_bib66","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2021010986","article-title":"Inferring the dynamics of mutated hematopoietic stem and progenitor cells\u00a0induced by IFN\u03b1 in myeloproliferative neoplasms","volume":"138","author":"Mosca","year":"2021","journal-title":"Blood"},{"issue":"19","key":"2023110216015419700_bib67","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A\u00a0randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia","volume":"139","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2023110216015419700_bib68","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/S2352-3026(19)30207-8","article-title":"Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study","volume":"7","author":"Kiladjian","year":"2020","journal-title":"Lancet Haematol"},{"issue":"7","key":"2023110216015419700_bib69","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1016\/S2352-3026(22)00102-8","article-title":"Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study","volume":"9","author":"Passamonti","year":"2022","journal-title":"Lancet Haematol"},{"issue":"4","key":"2023110216015419700_bib70","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ajh.23928","article-title":"Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b","volume":"90","author":"Them","year":"2015","journal-title":"Am J Hematol"},{"issue":"9","key":"2023110216015419700_bib71","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3324\/haematol.2019.235648","article-title":"Ruxolitinib and interferon-\u03b12 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study","volume":"105","author":"S\u00f8rensen","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"2023110216015419700_bib72","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"2023110216015419700_bib73","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1182\/blood.2019003347","article-title":"Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis","volume":"135","author":"Ronner","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2023110216015419700_bib74","doi-asserted-by":"crossref","first-page":"e721","DOI":"10.1097\/HS9.0000000000000721","article-title":"European LeukemiaNet response predicts disease progression but not thrombosis in polycythemia vera","volume":"6","author":"Tremblay","year":"2022","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"2023110216015419700_bib75","article-title":"Ruxolitinib versus best available therapy for PV intolerant or resistant to hydroxycarbamide in a randomized trial [abstract]","volume":"140","author":"Harrison","year":"2022","journal-title":"Blood"},{"key":"2023110216015419700_bib76","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/01.HS9.0000843676.80508.b5","article-title":"S196: ropeginterferon alfa-2B achieves patient-specific treatment goals in polycythemia vera: final results from the PROUD-PV\/CONTINUATION-PV studies","volume":"6","author":"Gisslinger","year":"2022","journal-title":"HemaSphere"},{"key":"2023110216015419700_bib77","article-title":"A\u00a0novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon-alpha2","author":"Dam","year":"2022","journal-title":"Cancer Med"},{"issue":"9","key":"2023110216015419700_bib78","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s00277-018-3365-y","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial","volume":"97","author":"Griesshammer","year":"2018","journal-title":"Ann Hematol"},{"issue":"suppl 1","key":"2023110216015419700_bib79","article-title":"Ropeginterferon Alfa-2b versus standard therapy for low-risk patients with polycythemia vera. Final results of low-PV randomized phase II trial [abstract]","volume":"140","author":"Barbui","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2023110216015419700_bib80","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"suppl 1","key":"2023110216015419700_bib81","article-title":"Combination therapy with ruxolitinib and interferon in newly diagnosed patients with polycythemia vera [abstract]","volume":"140","author":"S\u00f8rensen","year":"2022","journal-title":"Blood"},{"key":"2023110216015419700_bib82","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12185-022-03341-9","article-title":"Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study","volume":"116","author":"Edahiro","year":"2022","journal-title":"Int J Hematol"},{"issue":"suppl 1","key":"2023110216015419700_bib83","article-title":"JAK2V617F molecular response to ruxolitinib in patients with PV and ET is associated with lower risk of progression to secondary myelofibrosis [abstract]","volume":"140","author":"Guglielmelli","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2023110216015419700_bib84","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-018-0700-2","article-title":"Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?","volume":"41","author":"Hasselbalch","year":"2019","journal-title":"Semin Immunopathol"},{"issue":"suppl 1","key":"2023110216015419700_bib85","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2020-141223","article-title":"Interferon-alpha (IFN) therapy discontinuation is feasible in myeloproliferative neoplasm (MPN) patients with complete hematological remission [abstract]","volume":"136","author":"Daltro De Oliveira","year":"2020","journal-title":"Blood"},{"issue":"2","key":"2023110216015419700_bib86","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3109\/10428194.2015.1049171","article-title":"Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera","volume":"57","author":"Utke Rank","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2023110216015419700_bib87","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1038\/s41467-022-29381-7","article-title":"Discovery of a signaling feedback circuit that\u00a0defines interferon responses in myeloproliferative neoplasms","volume":"13","author":"Saleiro","year":"2022","journal-title":"Nat Commun"},{"issue":"7","key":"2023110216015419700_bib88","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1182\/bloodadvances.2021004856","article-title":"Genomic profiling of a randomized trial of interferon-\u03b1 versus hydroxyurea in MPN reveals mutation-specific responses","volume":"6","author":"Knudsen","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"2023110216015419700_bib89","doi-asserted-by":"crossref","first-page":"e0270669","DOI":"10.1371\/journal.pone.0270669","article-title":"Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms","volume":"17","author":"Skov","year":"2022","journal-title":"PLoS One"},{"key":"2023110216015419700_bib90","author":"Hoffman","year":"2022"},{"issue":"1","key":"2023110216015419700_bib91","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1038\/s41467-022-32928-3","article-title":"Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm","volume":"13","author":"Rahman","year":"2022","journal-title":"Nat Commun"},{"issue":"18","key":"2023110216015419700_bib92","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1182\/blood.2021013925","article-title":"HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression","volume":"139","author":"Li","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2023110216015419700_bib93","article-title":"A randomized, open-label, multicenter, phase 2 study to evaluate the efficacy, safety, and pharmacokinetics of KRT-232 compared with\u00a0ruxolitinib in patients with phlebotomydependent polycythemia vera [abstract]","volume":"134","author":"Gotlib","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2023110216015419700_bib94","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1182\/bloodadvances.2021006043","article-title":"The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study","volume":"6","author":"Mascarenhas","year":"2022","journal-title":"Blood Adv"},{"issue":"18","key":"2023110216015419700_bib95","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1182\/blood.2020009138","article-title":"Therapeutic inhibition of HIF2\u03b1 reverses polycythemia and pulmonary hypertension in murine models of two human diseases","volume":"137","author":"Ghosh","year":"2021","journal-title":"Blood"},{"issue":"25","key":"2023110216015419700_bib96","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1182\/blood.2021014465","article-title":"BMP2\/SMAD pathway activation in JAK2\/p53-mutant megakaryocyte\/erythroid progenitors promotes leukemic transformation","volume":"139","author":"Li","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2023110216015419700_bib97","doi-asserted-by":"crossref","first-page":"e20201268","DOI":"10.1084\/jem.20201268","article-title":"JAK2V617F myeloproliferative neoplasm eradication by a novel interferon\/arsenic therapy involves PML","volume":"218","author":"Dagher","year":"2021","journal-title":"J\u00a0Exp Med"},{"issue":"5","key":"2023110216015419700_bib98","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1080\/09537104.2021.1981850","article-title":"Mutated JAK2 signal transduction in human induced pluripotent stem cell (iPSC)-derived megakaryocytes","volume":"33","author":"Pawinwongchai","year":"2022","journal-title":"Platelets"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/16\/1934\/2087794\/blood_bld-2022-017697-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/16\/1934\/2087794\/blood_bld-2022-017697-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T12:04:20Z","timestamp":1698926660000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/141\/16\/1934\/494354\/JAK2V617F-allele-burden-in-polycythemia-vera"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":98,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,4,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022017697","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]}}}